Diana Spencer - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Diana Spencer's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Diana Spencer
Verified
Senior Digital Content Editor, Drug Discovery World
Edinburgh
Beats
lifestyleParenting family
books reviews, products, for-profit enterprises
Content
By Diana Spencer Verified| Drug Discovery World Verified MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity. DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). In the 28-day, 36-subject MAD portion of the study, DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity.
By Diana Spencer Verified| Drug Discovery World Verified Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.
By Diana Spencer Verified| Drug Discovery World Verified MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity. DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). In the 28-day, 36-subject MAD portion of the study, DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity.
Company Info
Drug Discovery World
London, England, United Kingdom
+44 20 8487 5656